BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 23600098)

  • 1. Unique association of myeloid neoplasm with eosinophilia and abnormalities of PDGFRA with TTP.
    Chaudhary LN; Bailey NG; Vos JA; Stotler CJ
    W V Med J; 2013; 109(2):6-9. PubMed ID: 23600098
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Myeloid neoplasm with rearrangement of PDGFRA, but with no significant eosinophilia: should we broaden the World Health Organization definition of the entity?
    Rudzki Z; Giles L; Cross NC; Lumley M
    Br J Haematol; 2012 Mar; 156(5):558. PubMed ID: 22224867
    [No Abstract]   [Full Text] [Related]  

  • 3. [Characteristics of cytogenetics and molecular biology in patients with eosinophilia].
    Qu SQ; Ai XF; Li CW; Li QH; Xu ZF; Qin TJ; Zhang Y; Xiao ZJ
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Oct; 20(5):1216-20. PubMed ID: 23114151
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Imatinib Treatment of Lymphomatoid Papulosis Associated with Myeloproliferative Hypereosinophilic Syndrome Presenting the FIP1L1-PDGFRA Fusion Gene.
    García-Martínez P; Sitjas D; Llistosella E; Espinet B; Rodríguez-Rivera M; Hernandez-Muñoz M; Gallardo F; Pujol RM
    Acta Derm Venereol; 2017 Jul; 97(7):855-857. PubMed ID: 28374041
    [No Abstract]   [Full Text] [Related]  

  • 5. A diagnostically difficult case of chronic myeloid neoplasm with eosinophilia and abnormalities of PDGFRA effectively treated with imatinib in accelerated phase: case report.
    Rodzaj M; Gałazka K; Majewski M; Zduńczyk A
    Pol Arch Med Wewn; 2009 Dec; 119(12):838-41. PubMed ID: 20010473
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical features of hypereosinophilic syndrome: FIP1L1-PDGFRA fusion gene-positive disease is a distinct clinical entity with myeloproliferative features and a poor response to corticosteroid.
    Miyazawa K; Kakazu N; Ohyashiki K
    Int J Hematol; 2007 Jan; 85(1):5-10. PubMed ID: 17261495
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A case of myeloid neoplasm with FIP1L1-PDGFRA rearrangement without marked peripheral blood eosinophilia.
    Wang J; Zhang Q; Zeng H; Chen B; Ouyang J
    Pharmacogenomics; 2016; 17(2):99-102. PubMed ID: 26666578
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Myeloid neoplasms with eosinophilia and FIP1L1-PDGFRA fusion gene: another point of view.
    Helbig G; Kyrcz-Krzemien S
    Leuk Lymphoma; 2013 Apr; 54(4):897-8. PubMed ID: 23025324
    [No Abstract]   [Full Text] [Related]  

  • 9. Idiopathic hypereosinophilic syndrome in children: report of a 7-year-old boy with FIP1L1-PDGFRA rearrangement.
    Rives S; Alcorta I; Toll T; Tuset E; Estella J; Cross NC
    J Pediatr Hematol Oncol; 2005 Dec; 27(12):663-5. PubMed ID: 16344672
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Myeloid neoplasm with prominent eosinophilia and PDGFRA rearrangement treated with imatinib mesylate.
    Rathe M; Kristensen TK; Møller MB; Carlsen NL
    Pediatr Blood Cancer; 2010 Oct; 55(4):730-2. PubMed ID: 20589620
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Blood and Bone Marrow Evaluation for Eosinophilia.
    Boyer DF
    Arch Pathol Lab Med; 2016 Oct; 140(10):1060-7. PubMed ID: 27684977
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A challenging diagnosis of myeloid/lymphoid neoplasm with eosinophilia and FIP1L1::PDGFRA rearrangement.
    Coltro G; Santi R
    Blood; 2023 May; 141(20):2541. PubMed ID: 37200055
    [No Abstract]   [Full Text] [Related]  

  • 13. Detection of FIP1L1-PDGFRA fusion by FISH.
    Ma ES; Wong KF; Wong CL; Siu LL
    Br J Haematol; 2007 Aug; 138(3):279. PubMed ID: 17542982
    [No Abstract]   [Full Text] [Related]  

  • 14. [Identification of FIP1L1-PDGFRA fusion, and expression of signal transducer and activator of transcription 5 in hypereosinophilic syndrome].
    Zhang GS; Li B; Pei MF; Dai CW; Zheng WL; Shen JK
    Zhonghua Yi Xue Za Zhi; 2004 Sep; 84(18):1541-4. PubMed ID: 15500716
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Platelet-derived growth factor receptor-alpha-associated hypereosinophilic syndrome and lymphomatoid papulosis.
    McPherson T; Cowen EW; McBurney E; Klion AD
    Br J Dermatol; 2006 Oct; 155(4):824-6. PubMed ID: 16965435
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chronic eosinophilic leukaemia with FIP1L1-PDGFRA fusion and T6741 mutation that evolved from Langerhans cell histiocytosis with eosinophilia after chemotherapy.
    Ohnishi H; Kandabashi K; Maeda Y; Kawamura M; Watanabe T
    Br J Haematol; 2006 Sep; 134(5):547-9. PubMed ID: 16856885
    [No Abstract]   [Full Text] [Related]  

  • 17. Chronic eosinophilic leukemias and the myeloproliferative variant of the hypereosinophilic syndrome.
    Bain BJ; Fletcher SH
    Immunol Allergy Clin North Am; 2007 Aug; 27(3):377-88. PubMed ID: 17868855
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Progressive multifocal leukoencephalopathy responsive to withdrawal of imatinib in a patient with FIP1L1-PDGFRA positive myeloid neoplasm.
    Blum S; Dunet V; Comoli P; Tirefort Y; Chalandon Y; Opota O; Comte D; Spertini O; Livio F; Brouland JP; Du Pasquier R
    Leuk Lymphoma; 2020 Sep; 61(9):2226-2229. PubMed ID: 32364409
    [No Abstract]   [Full Text] [Related]  

  • 19. Management of F/P+/- hypereosinophilic syndromes: case report and treatment review.
    Kalra A; Palaniswamy C; Kalra A; Wig N; Sood R
    Am J Ther; 2012 Sep; 19(5):e146-51. PubMed ID: 20724910
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Newly identified phenotypes in a FIP1L1/PDGFRA-associated paediatric HES patient: thrombocytosis, mHPA, young stroke and blindness.
    Zeng K; Li L; Huang L; Liang YH
    J Eur Acad Dermatol Venereol; 2015 Mar; 29(3):614-6. PubMed ID: 24576219
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.